$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

$csbr Overview Financials Valuation SEC Filings Company Website

2013 Q1 Form 10-K Financial Statement

#000114420413041406 Filed on July 26, 2013

Income Statement

Concept	2013 Q1	2013	2012 Q2
Revenue	$2.917M	$8.323M	$1.380M
YoY Change	21.54%	16.42%	-10.39%
Cost Of Revenue	$1.240M	$5.330M	$1.530M
YoY Change	-10.14%	8.78%	70.0%
Gross Profit	$1.680M	$3.000M	-$150.0K
YoY Change	64.71%	33.33%	-123.08%
Gross Profit Margin	57.59%	36.04%	-10.87%
Selling, General & Admin	$1.803M	$7.296M	$2.070M
YoY Change	-3.06%	-12.94%	-23.05%
% of Gross Profit	107.32%	243.2%
Research & Development	$592.0K	$1.920M	$380.0K
YoY Change	-36.34%	-34.69%	-51.9%
% of Gross Profit	35.24%	64.0%
Depreciation & Amortization	$51.00K	$203.0K	$40.00K
YoY Change	155.0%	93.33%	300.0%
% of Gross Profit	3.04%	6.77%
Operating Expenses	$3.637M	$14.54M	$2.450M
YoY Change	30.36%	-10.3%	-29.6%
Operating Profit	-$720.0K	-$6.221M	-$2.600M
YoY Change	-59.32%	-31.37%	-8.13%
Interest Expense	-$260.0K	-$70.00K	$60.00K
YoY Change	-471.43%	-116.67%	-250.0%
% of Operating Profit
Other Income/Expense, Net	-$265.0K	-$99.00K	-$10.00K
YoY Change	2550.0%	-124.63%	-107.14%
Pretax Income	-$985.0K	-$6.320M	-$2.550M
YoY Change	-42.73%	-27.05%	-6.59%
Income Tax	$5.000K	$10.00K	$0.00
% Of Pretax Income
Net Earnings	-$990.0K	-$6.330M	-$2.550M
YoY Change	-42.44%	-26.91%	-6.93%
Net Earnings / Revenue	-33.94%	-76.05%	-184.78%
Basic Earnings Per Share
Diluted Earnings Per Share	-$248.7K	-$1.459M	-$885.4K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q1	2013	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$10.77M	$9.560M	$4.720M
YoY Change	66.2%	101.26%	-54.88%
Cash & Equivalents	$10.77M	$9.560M	$4.754M
Short-Term Investments
Other Short-Term Assets	$300.0K	$320.0K	$210.0K
YoY Change	172.73%	52.38%	-25.0%
Inventory
Prepaid Expenses
Receivables	$640.0K	$500.0K	$584.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$11.71M	$10.38M	$5.543M
YoY Change	54.28%	87.36%	-53.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$440.0K	$410.0K	$560.0K
YoY Change	-2.22%	-26.79%	273.33%
Goodwill			$669.0K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$190.0K	$190.0K	$190.0K
YoY Change	26.67%	26.67%
Total Long-Term Assets	$1.300M	$1.270M	$1.379M
YoY Change	1.56%	-7.97%	70.25%
TOTAL ASSETS
Total Short-Term Assets	$11.71M	$10.38M	$5.543M
Total Long-Term Assets	$1.300M	$1.270M	$1.379M
Total Assets	$13.01M	$11.65M	$6.922M
YoY Change	46.67%	68.35%	-45.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.100M	$1.200M	$1.676M
YoY Change	-32.1%	-28.57%	6.08%
Accrued Expenses	$570.0K	$610.0K	$625.0K
YoY Change	67.65%	-3.17%	108.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.680M	$2.930M	$3.486M
YoY Change	-22.77%	-16.05%	-0.4%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$990.0K	$1.050M	$560.0K
YoY Change	59.68%	87.5%	-42.27%
Total Long-Term Liabilities	$990.0K	$1.050M	$560.0K
YoY Change	59.68%	87.5%	-42.27%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.680M	$2.930M	$3.486M
Total Long-Term Liabilities	$990.0K	$1.050M	$560.0K
Total Liabilities	$3.680M	$3.980M	$4.041M
YoY Change	-10.02%	-1.49%	-9.6%
SHAREHOLDERS EQUITY
Retained Earnings			-$25.14M
YoY Change
Common Stock			$21.24M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)			$1.252M
YoY Change
Treasury Stock Shares			3.236M shares
Shareholders Equity	$9.340M	$7.680M	-$5.278M
YoY Change
Total Liabilities & Shareholders Equity	$13.01M	$11.65M	$6.922M
YoY Change	46.67%	68.35%	-45.28%

Cashflow Statement

Concept	2013 Q1	2013	2012 Q2
OPERATING ACTIVITIES
Net Income	-$990.0K	-$6.330M	-$2.550M
YoY Change	-42.44%	-26.91%	-6.93%
Depreciation, Depletion And Amortization	$51.00K	$203.0K	$40.00K
YoY Change	155.0%	93.33%	300.0%
Cash From Operating Activities	-$580.0K	-$4.292M	-$1.530M
YoY Change	41.46%	-17.89%	178.18%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	$57.00K	-$150.0K
YoY Change	-95.24%	-89.02%	275.0%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	-$10.00K	-$57.00K	-$150.0K
YoY Change	-95.24%	-89.02%	400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$9.100M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	9.200M	$9.141M	0.000
YoY Change		9323.71%	-100.0%
NET CHANGE
Cash From Operating Activities	-580.0K	-$4.292M	-1.530M
Cash From Investing Activities	-10.00K	-$57.00K	-150.0K
Cash From Financing Activities	9.200M	$9.141M	0.000
Net Change In Cash	8.610M	$4.792M	-1.680M
YoY Change	-1488.71%	-184.83%	-122.19%
FREE CASH FLOW
Cash From Operating Activities	-$580.0K	-$4.292M	-$1.530M
Capital Expenditures	-$10.00K	$57.00K	-$150.0K
Free Cash Flow	-$570.0K	-$4.349M	-$1.380M
YoY Change	185.0%	-24.31%	170.59%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013	csbr	Personalized Oncology Solutions PersonalizedOncologySolutions	2390000	USD
CY2012	csbr	Personalized Oncology Solutions PersonalizedOncologySolutions	2332000	USD
CY2013	csbr	Translational Oncology Solutions TranslationalOncologySolutions	5933000	USD
CY2012	csbr	Translational Oncology Solutions TranslationalOncologySolutions	4817000	USD
CY2013	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	8323000	USD
CY2012	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	7149000	USD
CY2013	csbr	Cost Of Personalized Oncology Solutions CostOfPersonalizedOncologySolutions	2672000	USD
CY2012	csbr	Cost Of Personalized Oncology Solutions CostOfPersonalizedOncologySolutions	2356000	USD
CY2013	csbr	Cost Of Translational Oncology Solutions CostOfTranslationalOncologySolutions	2656000	USD
CY2012Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	555000	USD
CY2013Q2	us-gaap	Liabilities Liabilities	3975000	USD
CY2012Q2	us-gaap	Liabilities Liabilities	4041000	USD
CY2013Q2	us-gaap	Redeemable Noncontrolling Interest Equity Common Carrying Amount RedeemableNoncontrollingInterestEquityCommonCarryingAmount	16882000	USD
CY2012Q2	us-gaap	Redeemable Noncontrolling Interest Equity Common Carrying Amount RedeemableNoncontrollingInterestEquityCommonCarryingAmount	8159000	USD
CY2013Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2012Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	10
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2012Q4	dei	Entity Public Float EntityPublicFloat	30000000	USD
CY2013Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2012Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	31133333	shares
CY2012Q2	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	12533333	shares
CY2012Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	10
CY2013Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	56075	shares
CY2012Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	56075	shares
CY2013Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2012Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38855003	shares
CY2012Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37740345	shares
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35643658	shares
CY2012Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34529000	shares
CY2013Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	3236000	shares
CY2012Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	3236000	shares
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9561000	USD
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4754000	USD
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	500000	USD
CY2012Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	584000	USD
CY2013Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	315000	USD
CY2012Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	205000	USD
CY2013Q2	us-gaap	Assets Current AssetsCurrent	10376000	USD
CY2012Q2	us-gaap	Assets Current AssetsCurrent	5543000	USD
CY2013Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	192000	USD
CY2012Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000	USD
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	414000	USD
CY2012Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	560000	USD
CY2013Q2	us-gaap	Goodwill Goodwill	669000	USD
CY2012Q2	us-gaap	Goodwill Goodwill	669000	USD
CY2013Q2	us-gaap	Assets Assets	11651000	USD
CY2012Q2	us-gaap	Assets Assets	6922000	USD
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1204000	USD
CY2012Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1676000	USD
CY2013Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	611000	USD
CY2012Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	625000	USD
CY2013Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1114000	USD
CY2012Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1185000	USD
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2929000	USD
CY2012Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3486000	USD
CY2013Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1046000	USD
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	39000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	14544000	USD
CY2012	us-gaap	Operating Expenses OperatingExpenses	16214000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-6221000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-9065000	USD
CY2013	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-74000	USD
CY2012	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	417000	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-25000	USD
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-15000	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-99000	USD
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	402000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6320000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8663000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10000	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-6330000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-8661000	USD
CY2012Q2	us-gaap	Common Stock Value CommonStockValue	38000	USD
CY2012Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6922000	USD
CY2013Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1252000	USD
CY2012Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1252000	USD
CY2013Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	23580000	USD
CY2012	csbr	Cost Of Translational Oncology Solutions CostOfTranslationalOncologySolutions	2543000	USD
CY2012Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	21204000	USD
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-31473000	USD
CY2012Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25143000	USD
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000	USD
CY2012Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-125000	USD
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	-9206000	USD
CY2012Q2	us-gaap	Stockholders Equity StockholdersEquity	-5278000	USD
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11651000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4631000	USD
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5450000	USD
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.12
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52046766	shares
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	46815000	shares
CY2013	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	25000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-57000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6305000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8718000	USD
CY2011Q2	us-gaap	Stockholders Equity StockholdersEquity	19000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3323000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2376000	USD
CY2012	csbr	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	98000	USD
CY2013	csbr	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	0	USD
CY2012	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2013	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2012	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-57000	USD
CY2013	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	25000	USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	2376000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	3323000	USD
CY2013	us-gaap	Depreciation Depreciation	203000	USD
CY2012	us-gaap	Depreciation Depreciation	105000	USD
CY2013	csbr	Increase Decrease In Account Receivable IncreaseDecreaseInAccountReceivable	-84000	USD
CY2012	csbr	Increase Decrease In Account Receivable IncreaseDecreaseInAccountReceivable	-1000	USD
CY2013	csbr	Increase Or Decrease In Grant Receivable IncreaseOrDecreaseInGrantReceivable	0	USD
CY2012	csbr	Increase Or Decrease In Grant Receivable IncreaseOrDecreaseInGrantReceivable	517000	USD
CY2013	csbr	Increase Decrease In Prepaid Deferred Expenses And Other Assets IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets	110000	USD
CY2012	csbr	Increase Decrease In Prepaid Deferred Expenses And Other Assets IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets	-71000	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-42000	USD
CY2012	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-150000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-472000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	96000	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-14000	USD
CY2012	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	323000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-71000	USD
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1495000	shares
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	519000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-57000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-519000	USD
CY2013	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	15000	USD
CY2012	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-54000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4807000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5703000	USD
CY2011Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10457000	USD
CY2013	csbr	Proceeds From Issuance Of Redeemable Common Shares And Warrants In Private Placement ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement	9141000	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-433000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4292000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5227000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	57000	USD
CY2012	csbr	Proceeds From Issuance Of Redeemable Common Shares And Warrants In Private Placement ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement	0	USD
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2012	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	97000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9141000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	97000	USD
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="clear:both;FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both;FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><em>Use of Estimates</em></strong></div> <div style="clear:both;FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both;FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 9pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div> </div>
CY2013	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	617000	USD
CY2013	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<div style="clear:both;FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both;FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong><em>Deferred Revenue</em></strong></div> <div style="clear:both;FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="clear:both;FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 9pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Deferred revenue represents payments received in advance for products to be delivered.  When products are delivered, deferred revenue is then recognized as earned.</div> </div>
CY2011Q1	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	27000000	USD
CY2012	us-gaap	Deferred Revenue Revenue Recognized DeferredRevenueRevenueRecognized	918000	USD
CY2012	us-gaap	Advertising Expense AdvertisingExpense	135000	USD
CY2013Q2	csbr	Estimated Fair Value Of Warrants EstimatedFairValueOfWarrants	1046000	USD
CY2012Q2	csbr	Estimated Fair Value Of Warrants EstimatedFairValueOfWarrants	555000	USD
CY2013Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	19000	USD
CY2012Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	14000	USD
CY2013Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	200000	USD
CY2012Q2	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	104000	USD
CY2013	us-gaap	Advertising Expense AdvertisingExpense	50000	USD
CY2012Q4	csbr	Exercise Of Options To One Time Royalty Fee ExerciseOfOptionsToOneTimeRoyaltyFee	880000	USD
CY2011	us-gaap	Deferred Revenue Refund Payments DeferredRevenueRefundPayments	1400000	USD
CY2013Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	59000	USD
CY2012Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	58000	USD
CY2013Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	549000	USD
CY2012Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	287000	USD
CY2013Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	179000	USD
CY2012Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	167000	USD
CY2012Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2000	USD
CY2013Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2000	USD
CY2013Q2	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	0	USD
CY2012Q2	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	216000	USD
CY2013Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	789000	USD
CY2012Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	730000	USD
CY2013Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	375000	USD
CY2012Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	170000	USD
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	17216872	shares
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16307705	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.88	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.9	pure
CY2013Q2	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	7000	USD
CY2013	us-gaap	Deferred Revenue Period Increase Decrease DeferredRevenuePeriodIncreaseDecrease	277000	USD
CY2013	csbr	Exercise Of Options To One Time Royalty Fee ExerciseOfOptionsToOneTimeRoyaltyFee	880000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	164344000	USD
CY2013Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	164344000	USD
CY2010	us-gaap	License Costs LicenseCosts	40000	CAD
CY2011	csbr	Proceeds From Option Exercises ProceedsFromOptionExercises	85000	CAD
CY2012Q2	csbr	Additional License Costs AdditionalLicenseCosts	45000	CAD
CY2013	us-gaap	Royalty Expense RoyaltyExpense	10000	CAD
CY2013Q2	csbr	Business Acquisition Contingent Consideration Potential Cash Payments BusinessAcquisitionContingentConsiderationPotentialCashPayments	3000000	USD
CY2013Q2	csbr	Accrued Annual Royalty Payment AccruedAnnualRoyaltyPayment	10000	CAD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.007	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.004	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.013	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.023	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.04	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.08	pure
CY2013Q2	csbr	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstanding	3276667	shares
CY2013	csbr	Warrant Expiration Date WarrantExpirationDate	2014-07-31
CY2012	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	50000	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.41
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.58
CY2011	csbr	Sharebased Compensation Arrangement By Sharebased Payment Award Options Service Based Vesting Provisions SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsServiceBasedVestingProvisions	5000000	shares
CY2011	csbr	Sharebased Compensation Arrangement By Sharebased Payment Award Options Service And Performancebased Vesting Provisions SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsServiceAndPerformancebasedVestingProvisions	5000000	shares
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	84000	USD
CY2013	csbr	Stock Compensation Expense Related To Nonvested Restricted Stock Awards StockCompensationExpenseRelatedToNonvestedRestrictedStockAwards	15000	USD
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	348581	shares
CY2010Q1	csbr	Stock Options Award Shares To Purchase Common Stock StockOptionsAwardSharesToPurchaseCommonStock	100000	shares
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	34000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2376000	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3323000	USD
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14866038	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	741250	shares
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2013	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	25000	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	551250	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1140833	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13890205	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	13890205	shares
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	11344454	shares
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.88
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.41
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2013	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	0.62
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.72
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.95
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.85
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.86
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
CY2013	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms1 ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1	P7Y
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y10M24D
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	89000000	USD
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	54000000	USD
CY2011Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14320948	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	551329	shares
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	14866038	shares
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.88
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.89
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y9M18D
CY2011Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1780000	USD
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M24D
CY2012	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms1 ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1	P7Y7M6D
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y7M6D
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7743830	shares
CY2011Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.88
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.77
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.17
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.94
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.60
CY2012Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2012Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	89000000	USD
CY2013Q1	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	18600000	shares
CY2013Q1	csbr	Common Stock Purchase Price CommonStockPurchasePrice	0.50
CY2013Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	9300000	USD
CY2013Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	500000	USD
CY2011Q1	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	12533333	shares
CY2011Q1	csbr	Common Stock Purchase Price CommonStockPurchasePrice	0.75
CY2011Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	9400000	USD
CY2011Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	500000	USD
CY2012	csbr	Increase Decrease In Warrants Fair Value IncreaseDecreaseInWarrantsFairValue	600000	USD
CY2013	csbr	Purchase Price Limit Percentage PurchasePriceLimitPercentage	0.1	pure
CY2013	csbr	Increase Decrease In Warrants Fair Value IncreaseDecreaseInWarrantsFairValue	1050000	USD
CY2013Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9100000	USD
CY2013	csbr	Purchase Price Percentage PurchasePricePercentage	0.010	pure
CY2013Q2	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	607000	USD
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	USD
CY2012	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-3000	USD
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-2000	USD
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2523000	USD
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-172000	USD
CY2012	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-68000	USD
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2763000	USD
CY2012	csbr	Federal Income Tax Valuation Allowance FederalIncomeTaxValuationAllowance	2523000	USD
CY2012	csbr	State And Local Income Tax Valuation Allowance StateAndLocalIncomeTaxValuationAllowance	172000	USD
CY2012	csbr	Foreign Income Tax Valuation Allowance ForeignIncomeTaxValuationAllowance	68000	USD
CY2012	csbr	Valuation Allowances ValuationAllowances	2763000	USD
CY2012	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2012	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	1000	USD
CY2012	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	-3000	USD
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000	USD
CY2013	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	8000	USD
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	10000	USD
CY2013	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-2258000	USD
CY2013	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-196000	USD
CY2013	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2013	csbr	Federal Income Tax Valuation Allowance FederalIncomeTaxValuationAllowance	2258000	USD
CY2013	csbr	State And Local Income Tax Valuation Allowance StateAndLocalIncomeTaxValuationAllowance	196000	USD
CY2013	csbr	Foreign Income Tax Valuation Allowance ForeignIncomeTaxValuationAllowance	0	USD
CY2013	csbr	Valuation Allowances ValuationAllowances	2454000	USD
CY2013	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	0	USD
CY2013	us-gaap	State And Local Income Tax Expense Benefit Continuing Operations StateAndLocalIncomeTaxExpenseBenefitContinuingOperations	2000	USD
CY2013	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	8000	USD
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.026	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.023	pure
CY2013	csbr	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.005	pure
CY2012	csbr	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.015	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.016	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.030	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.396	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.319	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.017	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.029	pure
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002	pure
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2013Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	89000	USD
CY2012Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	62000	USD
CY2013Q2	csbr	Deferred Tax Assets Deferred Expense Depreciation And Amortization DeferredTaxAssetsDeferredExpenseDepreciationAndAmortization	51000	USD
CY2012Q2	csbr	Deferred Tax Assets Deferred Expense Depreciation And Amortization DeferredTaxAssetsDeferredExpenseDepreciationAndAmortization	80000	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2012	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2013Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2012Q2	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	5000	USD
CY2013Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3582000	USD
CY2012Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2685000	USD
CY2013Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	688000	USD
CY2012Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	798000	USD
CY2013Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	365000	USD
CY2012Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	265000	USD
CY2013Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4144000	USD
CY2012Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2478000	USD
CY2013Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	8926000	USD
CY2012Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	6373000	USD
CY2013Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	8926000	USD
CY2012Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6373000	USD
CY2012	us-gaap	Interest Paid InterestPaid	0	USD
CY2012Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2013	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-2454000	USD
CY2012	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	20000	USD
CY2013	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	0	USD
CY2013	csbr	Warrants Exercise Price Per Share WarrantsExercisePricePerShare	0.66
CY2013	csbr	Warrants Issued During Period For Common Stock WarrantsIssuedDuringPeriodForCommonStock	100000	shares
CY2013	us-gaap	Interest Paid InterestPaid	0	USD
CY2013	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
CY2012	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	192000	USD
CY2010	us-gaap	Revenue From Grants RevenueFromGrants	1500000	USD
CY2010Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	1000000	USD
CY2011	csbr	Qualifying Expenses QualifyingExpenses	500000	USD
CY2010	csbr	Qualifying Expenses QualifyingExpenses	1000000	USD
CY2012Q1	us-gaap	Grants Receivable Current GrantsReceivableCurrent	500000	USD

Files In Submission

Name	View Source	Status
0001144204-13-041406-index-headers.html	Edgar Link	pending
0001144204-13-041406-index.html	Edgar Link	pending
0001144204-13-041406.txt	Edgar Link	pending
0001144204-13-041406-xbrl.zip	Edgar Link	pending
csbr-20130430.xml	Edgar Link	completed
csbr-20130430.xsd	Edgar Link	pending
csbr-20130430_cal.xml	Edgar Link	unprocessable
csbr-20130430_def.xml	Edgar Link	unprocessable
csbr-20130430_lab.xml	Edgar Link	unprocessable
csbr-20130430_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R37.htm	Edgar Link	pending
R37.xml	Edgar Link	unprocessable
R38.htm	Edgar Link	pending
R38.xml	Edgar Link	unprocessable
R39.htm	Edgar Link	pending
R39.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R40.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
R41.xml	Edgar Link	unprocessable
R42.htm	Edgar Link	pending
R42.xml	Edgar Link	unprocessable
R43.htm	Edgar Link	pending
R43.xml	Edgar Link	unprocessable
R44.htm	Edgar Link	pending
R44.xml	Edgar Link	unprocessable
R45.htm	Edgar Link	pending
R45.xml	Edgar Link	unprocessable
R46.htm	Edgar Link	pending
R46.xml	Edgar Link	unprocessable
R47.htm	Edgar Link	pending
R47.xml	Edgar Link	unprocessable
R48.htm	Edgar Link	pending
R48.xml	Edgar Link	unprocessable
R49.htm	Edgar Link	pending
R49.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R50.htm	Edgar Link	pending
R50.xml	Edgar Link	unprocessable
R51.htm	Edgar Link	pending
R51.xml	Edgar Link	unprocessable
R52.htm	Edgar Link	pending
R52.xml	Edgar Link	unprocessable
R53.htm	Edgar Link	pending
R53.xml	Edgar Link	unprocessable
R54.htm	Edgar Link	pending
R54.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v349967_10k.htm	Edgar Link	pending
v349967_ex31-1.htm	Edgar Link	pending
v349967_ex31-2.htm	Edgar Link	pending
v349967_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

2013 Q1 Form 10-K Financial Statement

#000114420413041406 Filed on July 26, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR CHAMPIONS ONCOLOGY, INC. Stock $csbr

2013 Q1 Form 10-K Financial Statement

#000114420413041406 Filed on July 26, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr